MedPath

IMBiotechnologies Ltd

🇨🇦Canada
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:3

Trial Phases

1 Phases

Not Applicable:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Not Applicable
3 (100.0%)

OCL 500 Treatment of Women With Symptomatic Uterine Fibroids

Not Applicable
Completed
Conditions
Uterine Fibroid
Leiomyoma
Myoma
First Posted Date
2018-02-09
Last Posted Date
2019-09-12
Lead Sponsor
IMBiotechnologies Ltd.
Target Recruit Count
12
Registration Number
NCT03427671
Locations
🇨🇦

University of Alberta Hospital, Edmonton, Alberta, Canada

Safety and Efficacy of OCL 503 in Prostate Artery Embolization

Not Applicable
Completed
Conditions
Benign Prostatic Hyperplasia
Benign Prostatic Hypertrophy
First Posted Date
2015-07-28
Last Posted Date
2018-08-08
Lead Sponsor
IMBiotechnologies Ltd.
Target Recruit Count
10
Registration Number
NCT02509975
Locations
🇨🇦

University of Alberta Hospital, Edmonton, Alberta, Canada

Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata

Not Applicable
Completed
Conditions
Leiomyomata
First Posted Date
2015-04-07
Last Posted Date
2018-12-05
Lead Sponsor
IMBiotechnologies Ltd.
Target Recruit Count
3
Registration Number
NCT02410018
Locations
🇺🇸

Albany Medical Center, Albany, New York, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath